Johnson & Johnson Q2 2026 Earnings Recap

Shares declined 1.5% following Johnson & Johnson’s Q2 earnings despite management’s positive tone, reflecting investor caution over modest MedTech growth and cautious outlook signals amid mixed momentum across segments.

Key Takeaways

• Reported operational sales growth was 5.6% overall, with Innovative Medicine up 6.8% and MedTech growing only 3.6%.
• Oncology remains a key growth driver, led by DARZALEX exceeding $4 billion in sales and nearly 18% growth, alongside strong early adoption of ICOTYDE and robust growth from CARVYKTI, TECVAYLI, and TALVEY.
• Immunology showed impressive gains, with TREMFYA sales up 71% and successful expansion in indications like inflammatory bowel disease and myasthenia gravis.
• Neuroscience products CAPLYTA and SPRAVATO showed encouraging new patient starts and momentum following regulatory approvals.
• MedTech’s slower 3.6% growth and no further detail on margin expansion raised concerns about segment momentum in a competitive market environment.